Background. Streptozotocin (STZ) is a diabetogenic compound used to induce diabetes mellitus (DM) in animal models. A dose of 45–65 mg/kgBW of STZ triggers the destruction of pancreatic beta cells, resulting in a more stable hyperglycemic condition. Hyperglycemia, as a common feature of DM, leads to metabolic disturbances that cause oxidative stress and dyslipidemia. STZ at a dose of 60 mg/kg…